# Qubit Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/qubit-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Paris, France
- Website: www.qubit-pharmaceuticals.com
- Total disclosed funding: $12M
- Latest round: Series A (Jun 28, 2022)
- Investors on record: 3

## About

Qubit Pharmaceuticals is a French company specializing in advanced drug discovery and design, utilizing quantum physics and artificial intelligence to develop innovative drug candidates aimed at addressing complex biological targets.Founded in 2020 in Paris, France, Qubit Pharmaceuticals focuses on harnessing cutting-edge technology for drug discovery. It was established by a team including Jay Ponder and Jean-Philip Piquemal. The company has completed two deals, with the most recent in June 2022, raising EUR 11.35 mn in a Series A funding round led by Omnes Capital, XAnge, and returning investor Quantonation. The company operates from its headquarters in Paris and Boston, serving clients globally.Qubit Pharmaceuticals specializes in advanced drug discovery and design through its proprietary platform, Atlas. This technology leverages quantum physics and AI to create novel drug candidates. Their offerings include AI and machine learning solutions for modeling, as well as high-performance molecular dynamics software like TINKER-HP. They primarily target therapeutic areas such as oncology and inflammation and collaborate with various global partners to enhance drug candidate development.In 2022, Qubit Pharmaceuticals reported revenue of EUR 2,840,632.90 and an EBITDA loss of EUR 1,334,384.40. The company generates revenue through B2B partnerships with biotech firms and research institutions, focusing on milestone payments and licensing agreements for its proprietary technologies, including Atlas and TINKER-HP.Following its recent funding round on June 28, 2022, where Qubit Pharmaceuticals raised EUR 11.35 mn, the company plans to utilize these funds to strengthen its teams, enhance its proprietary Atlas software platform, and expand its pipeline of drug candidates. They are actively working on new product designs aimed at addressing unmet medical needs in oncology and inflammation, with a focus on expanding their market presence in North America, Europe, and Asia.

## Funding rounds

- Series A, Jun 28, 2022, $12M — Omnes Capital, XAnge, Quantonation

## Investors

- Omnes Capital (https://capitalatlas.ai/funds/omnes-capital) — Series A
- XAnge (https://capitalatlas.ai/funds/xange) — Series A
- Quantonation (https://capitalatlas.ai/funds/quantonation) — Series A